Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.60 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.56 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.56 |
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16697768 | 0.86 | CDK4 (0.75) | MAPTNPSR1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL31187476 | 0.86 | SRPK1 (0.74) | MAPTNPSR1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL22700680 | 0.86 | SRPK1 (0.74) | MAPTNPSR1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL3485720 | 0.86 | SRPK1 (0.74) | MAPTNPSR1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL23196345 | 0.85 | MAPT (0.52) | MAPTNPSR1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL20198520 | 0.81 | NPSR1 (0.72) | MAPTNPSR1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL23196454 | 0.79 | SRPK1 (0.53) | MAPTALDH1A1HPGDSRPK1KDR | |
| SCHEMBL3485920 | 0.73 | SRPK1 (0.98) | MAPTNPSR1TSHRALDH1A1HPGD | |
| SCHEMBL22700670 | 0.73 | KMT2A (0.71) | MAPTNPSR1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL3485343 | 0.73 | KMT2A (0.71) | MAPTNPSR1TSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210100781-A1 | TUMOR SUPPRESSION | KYOTO UNIVERSITY (JP) | 2021-04-08 | — | — | US | disclosed |
| WO-2020235672-A1 | PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE | 国立大学法人京都大学 (JP) | 2020-11-26 | — | — | WO | disclosed |
| US-20150133467-A1 | SCREENING METHOD, PROTEIN INSTABILITY AND/OR STABILITY INDUCERS, AND PROTEIN ACTIVITY ASSESSMENT | KYOTO UNIVERSITY (JP) | 2015-05-14 | — | — | US | disclosed |
| US-20150133467-A1 | SCREENING METHOD, PROTEIN INSTABILITY AND/OR STABILITY INDUCERS, AND PROTEIN ACTIVITY ASSESSMENT | KYOTO UNIVERSITY (JP) | 2015-05-14 | — | — | US | disclosed |
| US-20150133467-A1 | SCREENING METHOD, PROTEIN INSTABILITY AND/OR STABILITY INDUCERS, AND PROTEIN ACTIVITY ASSESSMENT | KYOTO UNIVERSITY (JP) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133467-A1 | SCREENING METHOD, PROTEIN INSTABILITY AND/OR STABILITY INDUCERS, AND PROTEIN ACTIVITY ASSESSMENT | IGF2BP1, IGF2BP2, IGF2BP3 | MAPT 3384/4885NPSR1 3633/4885TSHR 3338/4885 |
| US-20210100781-A1 | TUMOR SUPPRESSION | TSG101, TP53, VHL | MAPT 4590/4885NPSR1 1962/4885TSHR 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.